Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Operations (2023 - 2025)

Immunome's Cash from Operations history spans 3 years, with the latest figure at 47953000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 14.01% year-over-year to 47953000.0; the TTM value through Dec 2025 reached 190919000.0, down 72.32%, while the annual FY2025 figure was 190919000.0, 72.32% down from the prior year.
  • Cash from Operations reached 47953000.0 in Q4 2025 per IMNM's latest filing, down from 40510000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 24173000.0 in Q1 2023 to a low of 53055000.0 in Q1 2025.
  • Average Cash from Operations over 3 years is 25773416.67, with a median of 28782000.0 recorded in 2024.
  • The largest YoY upside for Cash from Operations was 14.01% in 2025 against a maximum downside of 374.98% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 17459000.0 in 2023, then crashed by 140.91% to 42060000.0 in 2024, then fell by 14.01% to 47953000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Cash from Operations are 47953000.0 (Q4 2025), 40510000.0 (Q3 2025), and 49401000.0 (Q2 2025).